The description of group-level, genotype-and phenotype-associated imaging traits is
academically important, but the practical demands of clinical neurology centre on the …

Amyotrophic lateral sclerosis (ALS) is associated with considerable clinical heterogeneity
spanning from diverse disability profiles, differences in UMN/LMN involvement, divergent …

Background: Oxidative stress and protein aggregation are key mechanisms in amyotrophic
lateral sclerosis (ALS) disease. Reduced glutathione (GSH) is the most important …

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease whose diagnosis
depends on the presence of combined lower motor neuron (LMN) and upper motor neuron …

A large multiparametric MRI study has been undertaken to evaluate anatomical patterns of
basal ganglia, white matter and cortical grey matter involvement in ALS. Unaffected brain …

Amyotrophic lateral sclerosis (ALS), also known as motor neuron disease, is an incurable
neurodegenerative condition, characterized by the loss of upper and lower motor neurons. It …

Background Despite significant advances in quantitative neuroimaging, the diagnosis of
ALS remains clinical and MRI-based biomarkers are not currently used to aid the diagnosis …

Background While neuroimaging in ALS has gained unprecedented momentum in recent
years, little progress has been made in the development of viable diagnostic, prognostic and …

Introduction The majority of imaging studies in ALS infer group-level imaging signatures
from group comparisons, as opposed to estimating disease burden in individual patients. In …

Background Diagnostic uncertainty in ALS has serious management implications and
delays recruitment into clinical trials. Emerging evidence of presymptomatic disease-burden …